US2018214558A1PendingUtilityA1

Cosmetic and pharmaceutical foam

69
Assignee: FOAMIX PHARMACEUTICALS LTDPriority: Oct 25, 2002Filed: Mar 29, 2018Published: Aug 2, 2018
Est. expiryOct 25, 2022(expired)· nominal 20-yr term from priority
Inventors:Dov TamarkinDoron FriedmanMeir Eini
A61P 37/06A61P 37/08A61P 5/00A61P 33/00A61P 35/00A61P 31/12A61P 31/10A61P 29/00A61P 31/04A61P 17/00A61P 17/02A61P 23/00A61P 17/16A61P 17/14A61P 1/00A61K 9/107A61K 9/0007A61K 47/06A61K 31/351A61K 9/12A61K 31/7048A61K 31/7036A61K 38/212A61K 31/573A61K 31/137A61Q 19/02A61K 38/12A61Q 17/02A61K 47/26A61Q 7/02A61K 47/14A61K 31/4164A61K 8/60A61K 9/0014A61K 9/0034A61K 2800/75A61K 31/522A61K 47/46A61K 31/535A61K 47/34A61K 47/20A61K 47/38A61K 31/567A61K 8/046A61Q 7/00A61Q 19/04A61K 9/122A01N 25/16A61K 31/4174A61K 47/10A61Q 17/04A61Q 19/08A61Q 19/007A61Q 19/00A61K 2800/30A61K 2800/244A61K 2800/242A61K 2800/24A61K 8/922A61K 8/87A61K 8/86A61K 8/8158A61K 8/8152A61K 8/736A61K 8/731A61K 8/4993A61K 8/42A61K 8/37A61K 8/362A61K 8/345A61K 8/34A61P 9/00A61P 31/00A61K 8/02A61K 9/00
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

Claims

exact text as granted — not AI-modified
1 - 87 . (canceled) 
     
     
         88 . A foamable pharmaceutical composition comprising:
 (a) azelaic acid;   (b) a hydrophobic solvent comprising isopropyl myristate, isopropyl palmitate and/or dimethyl isosorbide;   (c) a surfactant;   (d) a foam adjuvant;   (e) a gelling agent;   (f) a penetration enhancer comprising a triglyceride and/or propylene glycol;   (g) water; and   (h) a liquefied or compressed gas propellant; and   wherein the composition is capable of forming a breakable foam.   
     
     
         89 . The foamable pharmaceutical composition of  claim 88 , wherein the liquefied or compressed gas propellant is at a concentration of about 5% to about 25% by weight of the composition. 
     
     
         90 . The foamable pharmaceutical composition of  claim 88 , wherein the hydrophobic solvent is at a concentration of 2% to 75% by weight of the composition. 
     
     
         91 . The foamable pharmaceutical composition of  claim 88 , wherein the penetration enhancer comprises a triglyceride. 
     
     
         92 . The foamable pharmaceutical composition of  claim 91 , wherein the triglyceride comprises caprylic/capric triglyceride. 
     
     
         93 . The foamable pharmaceutical composition of  claim 88 , wherein the composition further comprises a preservative. 
     
     
         94 . The foamable pharmaceutical composition of  claim 88 , wherein the surfactant is at a concentration of about 0.1% to about 5% by weight of the composition. 
     
     
         95 . The foamable pharmaceutical composition of  claim 88 , wherein the surfactant is selected from the group consisting of polysorbates, mono or diglycerides, poly(oxyethylene) fatty acid esters, and a mixture of two or more thereof. 
     
     
         96 . The foamable pharmaceutical composition of  claim 95 , wherein the surfactant is selected from the group consisting of mono or diglycerides, polysorbate 80, and a mixture of two or more thereof. 
     
     
         97 . The foamable pharmaceutical composition of  claim 88 , wherein the foam adjuvant comprises one or more fatty alcohol having 15 or more carbons in its carbon chain. 
     
     
         98 . The foamable pharmaceutical composition of  claim 97 , wherein the foam adjuvant comprises cetyl alcohol, stearyl alcohol, or a mixture thereof. 
     
     
         99 . The foamable pharmaceutical composition of  claim 88 , wherein the gelling agent is at a concentration of about 0.1% to about 5% by weight of the composition. 
     
     
         100 . The foamable pharmaceutical composition of  claim 88 , wherein the gelling agent is selected from the group consisting of a naturally-occurring polymeric material, a cellulose ether, a polyacrylic acid polymer, and a mixture of any two or more thereof. 
     
     
         101 . The foamable pharmaceutical composition of  claim 88 , wherein the gelling agent is selected from the group consisting of a xanthan gum, a methyl cellulose, a polyacrylic acid polymer, and a mixture of any two or more thereof. 
     
     
         102 . A foamable pharmaceutical composition comprising:
 (a) azelaic acid;   (b) a hydrophobic solvent and/or a penetration enhancer, wherein the hydrophobic solvent and/or a penetration enhancer comprises one or more of isopropyl myristate, isopropyl palmitate, dimethyl isosorbide, a triglyceride and/or propylene glycol;   (c) a surfactant;   (d) a foam adjuvant;   (e) a gelling agent;   (f) water; and   (g) a liquefied or compressed gas propellant; and   wherein the composition is capable of forming a breakable foam.   
     
     
         103 . The foamable pharmaceutical composition of  claim 102 , wherein the liquefied or compressed gas propellant is at a concentration of about 5% to about 25% by weight of the composition. 
     
     
         104 . The foamable pharmaceutical composition of  claim 102 , wherein the hydrophobic solvent and/or penetration enhancer comprises one or more of isopropyl myristate, isopropyl palmitate, dimethyl isosorbide, and/or a triglyceride. 
     
     
         105 . The foamable pharmaceutical composition of  claim 102 , wherein the hydrophobic solvent is at a concentration of 2% to 75% by weight of the composition. 
     
     
         106 . The foamable pharmaceutical composition of  claim 102 , wherein the triglyceride comprises caprylic/capric triglyceride. 
     
     
         107 . The foamable pharmaceutical composition of  claim 102 , wherein the composition further comprises a preservative. 
     
     
         108 . The foamable pharmaceutical composition of  claim 102 , wherein the surfactant is at a concentration of about 0.1% to about 5% by weight of the composition. 
     
     
         109 . The foamable pharmaceutical composition of  claim 102 , wherein the surfactant is selected from the group consisting of polysorbates, mono or diglycerides, poly(oxyethylene) fatty acid esters, and a mixture of two or more thereof. 
     
     
         110 . The foamable pharmaceutical composition of  claim 109 , wherein the surfactant is selected from the group consisting of mono or diglycerides, polysorbate 80, and a mixture of two or more thereof. 
     
     
         111 . The foamable pharmaceutical composition of  claim 102 , wherein the foam adjuvant comprises one or more fatty alcohol having 15 or more carbons in its carbon chain. 
     
     
         112 . The foamable pharmaceutical composition of  claim 111 , wherein the foam adjuvant comprises cetyl alcohol, stearyl alcohol, or a mixture thereof. 
     
     
         113 . The foamable pharmaceutical composition of  claim 102 , wherein the gelling agent is at a concentration of about 0.1% to about 5% by weight of the composition. 
     
     
         114 . The foamable pharmaceutical composition of  claim 102 , wherein the gelling agent is selected from the group consisting of a naturally-occurring polymeric material, a cellulose ether, a polyacrylic acid polymer, and a mixture of any two or more thereof. 
     
     
         115 . The foamable pharmaceutical composition of  claim 102 , wherein the gelling agent is selected from the group consisting of a xanthan gum, a methyl cellulose, a polyacrylic acid polymer, and a mixture of any two or more thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.